Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
CJC-1295 (no DAC) + Ipamorelin
The CJC-1295 (no DAC) + Ipamorelin blend combines a structural analogue of growth hormone-releasing hormone (GHRH) with a selective agonist of the growth hormone secretagogue receptor (GHSR/ghrelin receptor). This combination is widely studied in research models exploring pharmacological synergy and the modulation of growth hormone secretagogues.
Specifications and Compliance:
Form: 10 mg total vial (dosage: 5 mg CJC-1295 no DAC + 5 mg Ipamorelin) as a lyophilized powder.
Purity: Certified ≥ 99% via HPLC analysis (accompanied by a batch-specific Certificate of Analysis/COA).
Packaging: Compliant with rigorous scientific experimental standards.
Regulatory Warning: Compound strictly reserved for in vitro research and laboratory use. It is not intended for human consumption, injection, or any therapeutic use. Handling and storage must adhere to laboratory safety protocols and applicable local regulations.
CJC-1295 (no DAC) + Ipamorelin
The CJC-1295 (no DAC) + Ipamorelin blend combines a structural analogue of growth hormone-releasing hormone (GHRH) with a selective agonist of the growth hormone secretagogue receptor (GHSR/ghrelin receptor). This combination is widely studied in research models exploring pharmacological synergy and the modulation of growth hormone secretagogues.
Specifications and Compliance:
Form: 10 mg total vial (dosage: 5 mg CJC-1295 no DAC + 5 mg Ipamorelin) as a lyophilized powder.
Purity: Certified ≥ 99% via HPLC analysis (accompanied by a batch-specific Certificate of Analysis/COA).
Packaging: Compliant with rigorous scientific experimental standards.
Regulatory Warning: Compound strictly reserved for in vitro research and laboratory use. It is not intended for human consumption, injection, or any therapeutic use. Handling and storage must adhere to laboratory safety protocols and applicable local regulations.